Abstract: MolMed developed a TK cell based therapy to enable safe and
effective haematopoietic stem cell transplantation (HSCT) from partially
compatible donors (haplo-HSCT), currently in clinical development for high-risk
leukaemia patients (AML and ALL). TK acquired the Orphan Drug status in EU
(2003) and in US (2005).
Keywords: Haematopoietic stem cell transplantation, TK cell based therapy, leukaemia